Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.

Gao HM, Zhang F, Zhou H, Kam W, Wilson B, Hong JS.

Environ Health Perspect. 2011 Jun;119(6):807-14. doi: 10.1289/ehp.1003013. Epub 2011 Jan 18.

2.

Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.

Perfeito R, Cunha-Oliveira T, Rego AC.

Free Radic Biol Med. 2013 Sep;62:186-201. doi: 10.1016/j.freeradbiomed.2013.05.042. Epub 2013 Jun 3. Review.

PMID:
23743292
4.

Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?

Olanow CW, Brundin P.

Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373. Review.

PMID:
23390095
5.

Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?

Fujita M, Sekigawa A, Sekiyama K, Sugama S, Hashimoto M.

J Neurol. 2009 Aug;256 Suppl 3:286-92. doi: 10.1007/s00415-009-5246-8. Review.

PMID:
19711118
6.

Proteomic approach to studying Parkinson's disease.

Zhang J, Goodlett DR.

Mol Neurobiol. 2004 Jun;29(3):271-88. Review.

PMID:
15181239
7.

Models of α-synuclein aggregation in Parkinson's disease.

Giráldez-Pérez R, Antolín-Vallespín M, Muñoz M, Sánchez-Capelo A.

Acta Neuropathol Commun. 2014 Dec 13;2:176. doi: 10.1186/s40478-014-0176-9. Review.

8.

The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.

Benskey MJ, Perez RG, Manfredsson FP.

J Neurochem. 2016 May;137(3):331-59. doi: 10.1111/jnc.13570. Epub 2016 Mar 23. Review.

9.
10.

Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.

Miraglia F, Betti L, Palego L, Giannaccini G.

Cent Nerv Syst Agents Med Chem. 2015;15(2):109-16. Review.

PMID:
25896035
11.

Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.

Xu S, Chan P.

Biomolecules. 2015 Jun 5;5(2):1122-42. doi: 10.3390/biom5021122. Review.

12.

α-Synuclein in Parkinson's disease: pathogenic function and translation into animal models.

Eschbach J, Danzer KM.

Neurodegener Dis. 2014;14(1):1-17. doi: 10.1159/000354615. Epub 2013 Sep 24. Review.

PMID:
24080741
13.

Neuropathology of synuclein aggregates.

Duda JE, Lee VM, Trojanowski JQ.

J Neurosci Res. 2000 Jul 15;61(2):121-7. Review.

PMID:
10878583
14.

The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models.

Sato H, Kato T, Arawaka S.

Rev Neurosci. 2013;24(2):115-23. doi: 10.1515/revneuro-2012-0071. Review.

PMID:
23314528
15.

Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention.

Tansey MG, Goldberg MS.

Neurobiol Dis. 2010 Mar;37(3):510-8. doi: 10.1016/j.nbd.2009.11.004. Epub 2009 Nov 10. Review.

16.

An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics.

Javed H, Kamal MA, Ojha S.

CNS Neurol Disord Drug Targets. 2016;15(10):1240-1252. Review.

PMID:
27658511
17.

Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?

Kanaan NM, Manfredsson FP.

J Parkinsons Dis. 2012;2(4):249-67. doi: 10.3233/JPD-012138. Review.

18.

How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?

Volpicelli-Daley LA, Kirik D, Stoyka LE, Standaert DG, Harms AS.

J Neurochem. 2016 Oct;139 Suppl 1:131-155. doi: 10.1111/jnc.13627. Epub 2016 May 4. Review.

19.

Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element.

Olivares D, Huang X, Branden L, Greig NH, Rogers JT.

Int J Mol Sci. 2009 Mar;10(3):1226-60. doi: 10.3390/ijms10031226. Epub 2009 Mar 17. Review.

20.

A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson's disease and potential molecular targets.

Ramsey CP, Tansey MG.

Exp Neurol. 2014 Jun;256:126-32. doi: 10.1016/j.expneurol.2013.05.014. Epub 2013 May 28. Review.

Supplemental Content

Support Center